论文部分内容阅读
由Onyx制药公司开发的carfilzomib(商品名:Kyprolis)于2012年7月20日获美国FDA批准,用于治疗曾接受过至少2种既往治疗方案[包括硼替佐米(商品名:Velcade)和免疫调节治疗]的多
Carfilzomib (trade name: Kyprolis), developed by Onyx Pharmaceuticals, was approved by the U.S. FDA on July 20, 2012 for the treatment of patients who have received at least 2 prior treatment regimens [including bortezomib (trade name: Velcade) Regulating treatment] much